Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.D-Pharm has reported a significantly higher recovery rate after stroke in its patients treated with its neuroprotective compound DP-b99, which has completed a phase IIb trial.
Subscribe to our email newsletter
The study also confirmed the excellent safety and tolerability profile of DP-b99, according to the Israel-based biopharmaceutical company. There was a significant two-fold increase in the number of patients achieving complete recovery from stroke (Modified Rankin scale) in the DP-b99 treated group compared to placebo (p=0.05).
A similar result was also found concerning recovery as judged by the NIHSS. When recovery includes either the Rankin or NIHSS definition, the significance of this result is even greater (p=0.02).
There was no difference in response to DP-b99 treatment between those patients treated within six hours or within six to nine hours following stroke onset.
Dr Alex Kozak, D-Pharm’s CEO and president, said: “The phase IIb results are really impressive and a great achievement. DP-b99 doubles the chances of patients with stroke to completely recover. We are now entering into strategic discussions to find the optimal path through late stage global clinical development towards marketing approvals.”